Asset Details
Do you wish to reserve the book?
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
Do you wish to request the book?
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
2023
Overview
Hepatocyte apoptosis plays an essential role in the progression of nonalcoholic steatohepatitis (NASH). However, the molecular mechanisms underlying hepatocyte apoptosis remain unclear. Here, we identify UDP-glucose 6-dehydrogenase (UGDH) as a suppressor of NASH-associated liver damage by inhibiting RIPK1 kinase-dependent hepatocyte apoptosis. UGDH is progressively reduced in proportion to NASH severity. UGDH absence from hepatocytes hastens the development of liver damage in male mice with NASH, which is suppressed by RIPK1 kinase-dead knockin mutation. Mechanistically, UGDH suppresses RIPK1 by converting UDP-glucose to UDP-glucuronate, the latter directly binds to the kinase domain of RIPK1 and inhibits its activation. Recovering UDP-glucuronate levels, even after the onset of NASH, improved liver damage. Our findings reveal a role for UGDH and UDP-glucuronate in NASH pathogenesis and uncover a mechanism by which UDP-glucuronate controls hepatocyte apoptosis by targeting RIPK1 kinase, and suggest UDP-glucuronate metabolism as a feasible target for more specific treatment of NASH-associated liver damage.
The mechanism underlying hepatocytes apoptosis, a key process in the progression of nonalcoholic steatohepatitis, remains unclear. Here, the authors identify UGDH and its catalytic product UDP-glucuronate as suppressors of NASH-associated liver damage by inhibiting RIPK1- dependent hepatocyte apoptosis.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/109
/ 13/2
/ 13/51
/ 13/89
/ 14/63
/ 38/77
/ 38/88
/ 64/60
/ 82/83
/ Animals
/ Damage
/ Glucose
/ Humanities and Social Sciences
/ Kinases
/ Liver
/ Male
/ Mice
/ Non-alcoholic Fatty Liver Disease - genetics
/ Non-alcoholic Fatty Liver Disease - metabolism
/ Receptor-Interacting Protein Serine-Threonine Kinases - genetics
/ Receptor-Interacting Protein Serine-Threonine Kinases - metabolism
/ Science
